全文获取类型
收费全文 | 240742篇 |
免费 | 37259篇 |
国内免费 | 2250篇 |
专业分类
耳鼻咽喉 | 6924篇 |
儿科学 | 7632篇 |
妇产科学 | 8671篇 |
基础医学 | 28473篇 |
口腔科学 | 8385篇 |
临床医学 | 33153篇 |
内科学 | 52216篇 |
皮肤病学 | 9525篇 |
神经病学 | 21934篇 |
特种医学 | 10185篇 |
外国民族医学 | 3篇 |
外科学 | 41766篇 |
综合类 | 1437篇 |
现状与发展 | 40篇 |
一般理论 | 7篇 |
预防医学 | 18353篇 |
眼科学 | 8245篇 |
药学 | 6597篇 |
中国医学 | 243篇 |
肿瘤学 | 16462篇 |
出版年
2023年 | 5693篇 |
2022年 | 2327篇 |
2021年 | 3653篇 |
2020年 | 6453篇 |
2019年 | 2982篇 |
2018年 | 9310篇 |
2017年 | 8759篇 |
2016年 | 8686篇 |
2015年 | 11763篇 |
2014年 | 14182篇 |
2013年 | 17260篇 |
2012年 | 7375篇 |
2011年 | 6916篇 |
2010年 | 10800篇 |
2009年 | 13250篇 |
2008年 | 7351篇 |
2007年 | 6242篇 |
2006年 | 7746篇 |
2005年 | 5841篇 |
2004年 | 4988篇 |
2003年 | 2957篇 |
2002年 | 1513篇 |
2001年 | 2854篇 |
2000年 | 2027篇 |
1999年 | 2972篇 |
1998年 | 3354篇 |
1997年 | 3195篇 |
1996年 | 3959篇 |
1995年 | 3456篇 |
1994年 | 2927篇 |
1993年 | 2536篇 |
1992年 | 2558篇 |
1991年 | 2233篇 |
1990年 | 1965篇 |
1989年 | 1792篇 |
1988年 | 1655篇 |
1987年 | 1615篇 |
1986年 | 1547篇 |
1933年 | 1493篇 |
1932年 | 1483篇 |
1931年 | 1472篇 |
1930年 | 1652篇 |
1929年 | 1389篇 |
1928年 | 1530篇 |
1927年 | 1497篇 |
1926年 | 1583篇 |
1925年 | 1544篇 |
1924年 | 1611篇 |
1923年 | 1465篇 |
1922年 | 1442篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
4.
5.
6.
7.
8.
9.
10.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献